Cue Health Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Cue Health is forecast to grow earnings and revenue by 51% and 38.4% per annum respectively. EPS is expected to grow by 68.7% per annum. Return on equity is forecast to be -46% in 3 years.
Anahtar bilgiler
51.0%
Kazanç büyüme oranı
68.7%
EPS büyüme oranı
Medical Equipment kazanç büyümesi | 17.4% |
Gelir büyüme oranı | 38.4% |
Gelecekteki özkaynak getirisi | -46.0% |
Analist kapsamı | Low |
Son güncelleme | 10 Apr 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Take Care Before Jumping Onto Cue Health Inc. (NASDAQ:HLTH) Even Though It's 26% Cheaper
May 10Investors Don't See Light At End Of Cue Health Inc.'s (NASDAQ:HLTH) Tunnel And Push Stock Down 26%
Mar 22Cue Health Inc.'s (NASDAQ:HLTH) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Jan 28We're A Little Worried About Cue Health's (NASDAQ:HLTH) Cash Burn Rate
Jan 06Investors Don't See Light At End Of Cue Health Inc.'s (NASDAQ:HLTH) Tunnel And Push Stock Down 28%
Nov 10These Analysts Think Cue Health Inc.'s (NASDAQ:HLTH) Sales Are Under Threat
Aug 14Can Cue Health (NASDAQ:HLTH) Afford To Invest In Growth?
Jul 12Revenue Downgrade: Here's What Analysts Forecast For Cue Health Inc. (NASDAQ:HLTH)
May 15Cue Health Inc. (NASDAQ:HLTH) Analysts Just Slashed This Year's Revenue Estimates By 56%
Mar 21We Think Cue Health (NASDAQ:HLTH) Needs To Drive Business Growth Carefully
Mar 12Cue Health Inc.'s (NASDAQ:HLTH) Intrinsic Value Is Potentially 44% Above Its Share Price
Feb 13Cue Health Inc. (NASDAQ:HLTH) Analysts Just Trimmed Their Revenue Forecasts By 24%
Nov 18Here's Why We're Not Too Worried About Cue Health's (NASDAQ:HLTH) Cash Burn Situation
Oct 30Cue Health applies for FDA emergency use nod for its flu & COVID-19 molecular test
Oct 04Cue Health appoints chief medical oficer
Sep 08Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 207 | -44 | N/A | N/A | 2 |
12/31/2025 | 110 | -170 | N/A | N/A | 3 |
12/31/2024 | 57 | -224 | N/A | N/A | 3 |
12/31/2023 | 71 | -373 | -158 | -138 | N/A |
9/30/2023 | 199 | -257 | -189 | -161 | N/A |
6/30/2023 | 251 | -276 | -231 | -188 | N/A |
3/31/2023 | 329 | -291 | -255 | -197 | N/A |
12/31/2022 | 483 | -194 | -175 | -112 | N/A |
9/30/2022 | 529 | -138 | -142 | -51 | N/A |
6/30/2022 | 683 | -67 | -83 | 8 | N/A |
3/31/2022 | 733 | 34 | -41 | 57 | N/A |
12/31/2021 | 618 | 33 | -125 | -9 | N/A |
9/30/2021 | 439 | -11 | -16 | 134 | N/A |
6/30/2021 | 220 | -24 | -60 | 76 | N/A |
3/31/2021 | 87 | -37 | -44 | 65 | N/A |
12/31/2020 | 23 | -47 | 15 | 93 | N/A |
12/31/2019 | 7 | -21 | -16 | -13 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: HLTH is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: HLTH is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: HLTH is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: HLTH's revenue (38.4% per year) is forecast to grow faster than the US market (8.4% per year).
Yüksek Büyüme Geliri: HLTH's revenue (38.4% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: HLTH is forecast to be unprofitable in 3 years.